ClinicalTrials.gg
CompletedNCT07033455Updated Nov 18, 2025

A Trial of HRS-1893 in Healthy Volunteers

An Early Phase 1 interventional study of HRS-1893 in Hypertrophic Cardiomyopathy, sponsored by Atridia Pty Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Cardiomyopathy, Hypertrophic with a site in Australia — 1 open to participants now, 5 under way, 3 of them phase 3. Cardiomyopathy, Hypertrophic · Australia.

Started
2025
the only one that year
Phase 1
Only one
of the 11
Registered
11th of 11
by date
Lead sponsor
1 of 11
Atridia Pty Ltd.

Among the 11 studies in Cardiomyopathy, Hypertrophic with a site in Australia, this one is the only one that started in 2025, is the only one in phase 1, and was the 11th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

1 of the 11 studies in Cardiomyopathy, Hypertrophic with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Cardiomyopathy, Hypertrophic with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and PK characteristics of a single oral dose of HRS-1893 in healthy voluunters.

03

Conditions studied

  • Hypertrophic Cardiomyopathy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy white participants;
  2. Ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written , be able to comply with all the requirements, and able to complete the study.
  3. Male aged between 18 to 55 years of age (inclusive)
  4. Women with body weight ≥ 45.0 kg, men with body weight ≥ 50.0 kg, (BMI) between 19.0 and 30.0 kg/m2 (inclusive) at screening.
  5. Negative pregnancy test for women of (WOCBP) at baseline. Men and WOCBP must agree to take highly effective methods

Exclusion criteria

Exclusion Criteria:

  1. History or evidence of disorders
  2. History of cardiomyopathy and/or unexplained heart failure
  3. Individuals with a history of drug allergies, specific allergies
  4. Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    HRS-1893 Dose level 1

    Single oral low dose of HRS-1893 (dose level 1)

    Drug: HRS-1893

  • Experimental
    HRS-1893 Dose level 2

    Single oral high dose of HRS-1893 (dose level 2)

    Drug: HRS-1893

Interventions

  • Single dose of HRS-1893 orally administered

06

What researchers measure

Primary outcomes

  1. PK profile of HRS-1893 after a single oral (PO) administration

    Pharmacokinetics PK Cmax: Plasma Cmax

    Time frame: Day 8

  2. PK profile of HRS-1893 after a single oral (PO) administration

    Pharmacokinetics PK AUClast : Plasma AUClast

    Time frame: Day 8

  3. PK profile of HRS-1893 after a single oral (PO) administration

    Pharmacokinetics PK AUC0-inf: Plasma AUC0-inf

    Time frame: Day 8

  4. PK profile of HRS-1893 after a single oral (PO) administration

    Pharmacokinetics PK Tmax :Plasma Tmax

    Time frame: Day 8

  5. PK profile of HRS-1893 after a single oral (PO) administration

    Pharmacokinetics PK t1/2 : Plasma t1/2

    Time frame: Day 8

  6. PK profile of HRS-1893 after a single oral (PO) administration

    Pharmacokinetics PK CL/F: Plasma CL/F

    Time frame: Day 8

  7. PK profile of HRS-1893 after a single oral (PO) administration

    Pharmacokinetics PK Vz/F: Plasma Vz/F

    Time frame: Day 8

  8. Cumulative amount of drug excreted in urine of HRS-1893 after a single oral administration

    Cumulative amount of drug excreted in urine (Ae,ur)

    Time frame: Day 8

  9. Cumulative percentage of dose recovered in urine of HRS-1893 after a single oral administration:

    Cumulative percentage of dose recovered in urine (%Ae,ur)

    Time frame: Day 8

  10. Renal clearance of HRS-1893 after a single oral administration

    Renal clearance (CLr)

    Time frame: Day 8

Secondary outcomes

  1. Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events

    Number of participants with Adverse events and Serious adverse events

    Time frame: Day 8

07

Study locations

1 site
  • Linear Clinical Research
    Nedlands, Western Australia 6009, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Sep 2025, 2 months.

Of 12 phase 1 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
Jun 24, 2025
StartActual
Jun 25, 2025
Primary completionActual
Sep 5, 2025
CompletionActual
Oct 30, 2025
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07033455
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Jun 25, 2025
Primary completion
Sep 5, 2025
Completion
Oct 30, 2025
Last update
Nov 18, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1893

Start the discussion